Literature DB >> 2472245

Cytoreduction in ovarian cancer: achievability and results.

M J Webb.   

Abstract

A series of 210 consecutive operations for ovarian cancer performed by the author over a five-year period were analysed in order to assess the ability to perform adequate cytoreduction. Over 63% of the patients had Stage III or IV disease. Bowel resection was necessary in 50 cases, and the surgery was generally well tolerated. Debulking was assessed as a percentage of tumour volume reduction and also by the size of residual tumour after operation. Over 90% tumour volume reduction was accomplished in 82.7% of all cases (75% of Stage III cases), and optimal cytoreduction of nodules to less than or equal to 1.5 cm was achieved in 70.8% of cases (60% of Stage III cases). Survival analysis confirmed the importance of cytoreduction in the management of this disease.

Entities:  

Mesh:

Year:  1989        PMID: 2472245     DOI: 10.1016/s0950-3552(89)80044-6

Source DB:  PubMed          Journal:  Baillieres Clin Obstet Gynaecol        ISSN: 0950-3552


  4 in total

1.  Endoscopic ultrasonography in the assessment of colonic wall invasion by adjacent diseases.

Authors:  N Hirata; K Kawamoto; T Ueyama; I Iwashita; K Masuda
Journal:  Abdom Imaging       Date:  1994 Jan-Feb

Review 2.  Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.

Authors:  Amin P Makar; Claes G Tropé; Philippe Tummers; Hannelore Denys; Katrien Vandecasteele
Journal:  Oncologist       Date:  2016-03-23

3.  An audit of surgical treatment of ovarian cancer in a metropolitan health region. Association of Obstetricians and Gynaecologists of the North East Thames Region.

Authors:  C N Hudson; P Potsides; O M Curling
Journal:  J R Soc Med       Date:  1991-04       Impact factor: 18.000

4.  The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

Authors:  J Fisken; R C Leonard; M Stewart; G J Beattie; C Sturgeon; L Aspinall; J E Roulston
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.